Nitroheterocycles

Overall, the potential for drug repurposing of any nitroheterocycles for HAT heavily depends on their toxicity–and notably genotoxicity/mutagenicity—profile in respect to their efficacy in relevant rodent models, as demonstrated by the successful development of fexinidazole currently in Phase III clinical trials [20, 21 ].